A Single and Multiple Ascending Dose study of AB-423 in in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 03 Oct 2017
At a glance
- Drugs AB 423 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- 03 Oct 2017 According to an Arbutus Biopharma media release, data from this trial will be presented at The Liver Meeting 2017 organized by the American Association for the Study of Liver Diseases (AASLD) 2017.
- 03 Aug 2017 According to an Arbutus Biopharma Corporation media release, top-line results from this trial are expected in the fourth quarter of 2017.
- 31 Mar 2017 Status changed from planning to recruiting, as reported in an Arbutus Biopharma media release.